title: Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?
authors.affiliation: Neuroscience Research Center, and Service of Neurosurgery, Lausanne University Hospital, Lausanne (CHUV) (M.E.H); Department of Oncology, University Hospital Zurich, Zurich, Switzerland (R.S).
authors.forename: Monika E
authors.initials: ME
authors.lastname: Hegi
authors.affiliation: Neuroscience Research Center, and Service of Neurosurgery, Lausanne University Hospital, Lausanne (CHUV) (M.E.H); Department of Oncology, University Hospital Zurich, Zurich, Switzerland (R.S).
authors.forename: Roger
authors.initials: R
authors.lastname: Stupp
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019175:DNA Methylation / Q000235:genetics; D015254:DNA Modification Methylases / Q000235:genetics*; D045643:DNA Repair Enzymes / Q000235:genetics*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D011401:Promoter Regions, Genetic / Q000235:genetics; D000077204:Temozolomide; D025521:Tumor Suppressor Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D025521:Tumor Suppressor Proteins; D003606:Dacarbazine; D015254:DNA Modification Methylases; C515491:MGMT protein, human; D045643:DNA Repair Enzymes; D000077204:Temozolomide